May 22, 2013
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™ Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented today at the annual EuroPCR Scientific Program in
, M.D., of the
Renal denervation with the Vessix System is a minimally-invasive procedure in which a balloon catheter is fed into the arterial vascular system and positioned in the renal arteries, the major blood vessels that lead to the kidneys. The physician then delivers low-power radiofrequency (RF) energy to disrupt the nerves surrounding the renal arteries in which hyperactivity leads to uncontrolled high blood pressure.
"Tens of thousands of patients worldwide have blood pressure that is high and uncontrolled, putting them at significantly increased risk for a variety of cardiovascular diseases, including heart attack, stroke and kidney failure," said Professor
, M.D., Ph.D., director of the CardioVascular Center Frankfurt, Sankt Katharinen Hospital, in
, and principal investigator in the REDUCE-HTN clinical program. "The interim data from REDUCE-HTN demonstrate that renal denervation with the Vessix System offers a significant and sustained blood pressure reduction in patients with uncontrolled hypertension. The familiar over-the-wire balloon platform of the Vessix System, the short procedure time and precise bipolar approach offer a significant step forward in the treatment of this challenging condition."
The REDUCE-HTN clinical program is evaluating the ability of the Vessix System to reduce blood pressure at six months as compared to the pre-treatment baseline blood pressure. Patients enrolled in the program are required to have a systolic blood pressure of at least 160 mmHg despite taking three or more antihypertensive medications.